APOLLO PHARMACY
These healthcare and pharma stocks may deliver more than 20% in one year
Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores. SR+ Reports is a complimentary offering to ETPrime members.
Kannada star Darshan served biryani behind bars after arrest for murdering fan
Renuka was murdered by Darshan and his associates for allegedly sending inappropriate messages and explicit photos to Darshan’s rumored girlfriend, Pavithra Gowda. Renuka, a 33-year-old pharmacy worker and fan of the actor leaves behind a pregnant widow, elderly parents, and grandparents.
ET Analysis: Indian hospital chains report revenue growth & expansion plans amidst regulatory concerns
Leading hospital chains in India have reported improved average revenue per operating bed (ARPOB) and profitability in the latest quarter, driven by better payer mix and cost control measures. Expansion plans are underway, with a focus on markets like Bengaluru and Mumbai, through asset-light models. Adjacent businesses such as diagnostics, virtual care, and digital healthcare platforms are also seeing growth. However, regulatory proposals to rationalize rates may pose risks to sector valuations.
Planning to invest Rs 3,000 crores to add 2,000 beds in 3 years: Suneeta Reddy, Apollo Hospitals
Let us look at both ARPOB, it is over 59,000, it is about Rs 59,0330. We have seen an increase in ARPOB of around 12%, but more importantly just going forward, this is because of a better case mix and price, but definitely improved case mix. With regard to volumes, inpatient volumes grew by 6%, outpatient volumes grew by 9%. And our ARPOB is net of doctors’ fees.
Apollo Hospitals Q4 Results: Net profit rises 76% YoY to Rs 254 crore
Revenue grew 15% YoY to Rs.4,944 crore in Q4FY24. The earnings before interest, tax, depreciation and ammortisation (EBITDA), EBITDA rose 31% YoY to Rs.640 crore in Q4FY24. The EBITDA margins expanded 161 basis points YoY to 12.95%.
Apollo Hospitals Q4 Results: Net profit soars 77% YoY to Rs 258 crore; revenue jumps 15%
Apollo Hospitals Q4 Results: Revenue from operations for the January-March 2024 period increased 15% YoY to Rs 4,944 crore. The company's board has recommended a final dividend of Rs 10 per share for FY24. EBITDA for the fourth quarter stood at Rs 640 crore in the reporting March quarter, compared with Rs 488 crore in the same quarter a year earlier.
- Go To Page 1
Apollo Hospitals Q4 results today: What to expect
Apollo Hospitals is expected to post healthy growth in core earnings for the quarter ended March 2024 due to improved ARPOB and Healthco operations. Analysts predict a 68% year-on-year growth in net profit for the fourth quarter.
Q4 results today: Apollo Hospitals among 895 companies to announce earnings on Thursday
Fourth quarter earnings season is wrapping up with 895 companies reporting results on Thursday. Investors keenly await Apollo Hospitals' results, expecting robust growth driven by improved ARPOB and HealthCo operations. Analysts predict up to a 68% YoY increase in net profit, with sales expected to rise by 13%.
Defensive stocks: FMCG is “passe”; 8 stocks from two sectors may be called “new defensives” with upside potential of up to 32%
1994 to 2024 is a difference of 30 years, but there is one thing which has remained constant, advice to move to defensive stocks when markets are volatile or there is an event risk. Four questions need to be asked; first, what is a defensive stock? Second, is a stock which was considered a defensive in 1994 when the Indian economy was just opening, still a defensive stock in 2024 ? Third, should there be a new definition of defensive stock in 2024 ? Last but not the least, what are the new defensive sectors or stocks?
Will short-term headwinds impact long-term potential? 6 stocks from hospital sector with upside potential of up to 30%
After outperforming the market, stocks from the healthcare sector or what is more commonly called hospital sector have gone into consolidation mode. The consolidation has been prompted by the fact that voices have been raised about differential pricing in the services of the hospitals. The matter has reached the Supreme Court and will be heard. Given the fact that while medicine is a science but in real life as practice it has an element of art in it. For example, a hospital who has a renowned surgeon from any branch, be it cardio, neuro on its roll may charge up more for the same surgery as compared to others. While the moral debate is on one side, there is another side to the story. In a country like India, the healthcare infrastructure needs vast expansion and upgradation. To some extent the street is ruthless and does not have much moral obligation.
Valuation of Apollo HealthCo will go up by many multiples due to integration of Keimed: Suneeta Reddy, Apollo Hospitals
The most important segment, of course, is the offline pharmacy currently and that segment if you look at the growth, it is happening at 20%. Online is growing much faster at over 70%, so this has been reflected in the growth in GMV.
Apollo Hospitals share price falls 8% post stake sale and Keimed merger
The brokerage has reduced its pharmacy target valuation from 25x to 22x, resulting in a lower SoTP by Rs 290 per share. "Keeping the hospital multiple intact (24x) and rolling over to FY26, our revised target price is Rs 7,300 (from Rs 7,500); we maintain ‘BUY’," it said.
PE Advent International queues up for a stake in Apollo 24/7
Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.
Fundamental Radar: Three factors to drive 15% sales CAGR for Apollo Hospitals, says Sneha Poddar
Apollo Hospitals is implementing efforts across segments – adding 2,000 beds over the next three years, improving payor mix to drive better ARPOB, and building tailwinds for GMV (gross merchandise value) growth as well as improving operational efficiency.
We will look at increasing tariff next year: Suneeta Reddy, Apollo Hospitals
I think store on store growth is improving consistently. So when are we going to break even, I think we have assured all our investors that within the next six quarters, we will break in on the whole, with both online and offline, both of them showing profitability.
Apollo Hospitals Q3 Results: Net profit rises 60% YoY to Rs 245 crore
Apollo Hospitals on Thursday reported a 60% year-on-year (YoY) jump in net profit to Rs 245 crore in Q3FY24, led by growth across hospital, diagnostics, speciality and pharmacies businesses.
Apollo Hospitals Q3 Results: Cons PAT soars 59% YoY to Rs 245 crore; dividend declared at Rs 6/share
Apollo Hospitals' revenue from operations grew 14% YoY to Rs 4,851 crore, and topped the estimated Rs 4,771 crore. The healthcare services business saw a healthy 13% YoY growth in revenue during the quarter to Rs 2,483 crore, followed by the pharmacy distribution business housed under Apollo Pharmacy, which registered 17% growth in revenue to Rs 2,049 crore.
Hot Stocks: 3 concerns behind $13 bn rout in HDFC Bank; brokerages downgrade LTIMindtree
Brokerage firm Bernstein maintained an outperform rating on HDFC Bank, Nomura maintained a buy rating on Apollo Hospitals, InCred downgraded LTIMindtree and Goldman Sachs maintained a neutral rating on Asian Paints.
Boots owner in talks to offload $9-billion UK pharmacy chain
Walgreens Boots Alliance has been holding early talks about ways to separate Boots, which could be valued at about £7 billion ($8.8 billion), according to the people. It's studying a London initial public offering as one possibility, the people said.
Ready to see new capex deliver, Apollo can ill afford a blemish
Apollo Hospitals is one of the most integrated healthcare players in the country with a presence across various aspects of the healthcare value chain - hospitals, pharmacies, clinics, diagnostics, and insurance. It has the largest hospital chain in the country, including 71 facilities that together have 9,789 beds, and the business has a market value just shy of ₹80,000 crore.
1mg overtakes PharmEasy in market share in top order change
Tata 1mg had a 31% market share in September 2023 against 19% in October 2022 while PharmEasy slipped to 15% from about 33% during the same period, according to a data analysis by third-party internet market research firm Redseer, which ET has seen.
There is room for us to take debt, but it is not required this year: Suneeta Reddy, Apollo Hospitals
“This year, there is no need for immediate cash infusion in Apollo HealthCo. It is being supported by Rs 130 crore of EBITDA coming from the backend pharmacy. So, there is cash for growth existing within the company and at the right valuation, we will look at a 10% dilution.”
Apollo Hospitals to invest Rs 3435 crore on capacity expansion, posts Rs 233 cr net profit in Q2
As part of the expansion plan, the company announced a 250-bed new hospital in Pune expandable to 425 beds in 2 years at an overall cost of Rs 675 crores. The hospital is expected to be commissioned by Q1 FY25. With this expansion, Apollo will have over 1000 beds in Maharashtra including Mumbai, Pune and Nashik.
Apollo Hospitals Q2 Results: Consolidated PAT jumps 14% YoY to Rs 233 crore, meets estimate
The revenue for the quarter stood at Rs 4,846.90 crore, also up by 14% YoY.
Apollo Hospitals plans digital arm stake sale
It reported revenues of ₹6,705 crore and loss of ₹304 crore in FY23. While the offline pharmacy distribution business generated earnings before interest, tax, depreciation and amortisation (Ebitda) of ₹534 crore in FY23, growing 31% year-on-year (YoY), the digital health business has been burning cash on an average to the tune of ₹180 crore per quarter.
Looking forward to outstanding performance from offline pharmacy: Suneeta Reddy, Apollo Hospitals
Yes, by the fourth quarter, we will be EBITDA neutral and I think that we are working towards that. Most of our expenditure has already been incurred and as the revenues pick up, we will be EBITDA neutral.
How online pharmacies have landed in a regulatory limbo
The lack of regulatory clarity is imperiling India’s online pharmacy sector. While the digital business has grown rapidly in the past few years, online pharmacies have been accused of irrational use of prescription drugs, unlicensed selling of drugs, and endangering patients’ area-wise data. They are also reportedly selling drugs without licences, which neither the existing drug laws nor the draft amendment rules are governing. As a chemists’ organisation recently demanded a ban on online pharmacies, the government is preparing to replace existing drug regulations with the New Drugs, Medical Devices and Cosmetics Bill, 2023, which is expected to bring in more stringent norms for the sector.
After notices, e-pharmacies look to make a case to government
The proposed regulation seeks to include a clause that empowers the government to “regulate, restrict or prohibit” any sale, stocking or distribution of any drug by online mode, by issuing a notification”.
Centre mulls regulations, stringent action against e-pharmacies amid concerns over data privacy, malpractices
The New Drugs, Medical Devices and Cosmetics Bill, 2023, seeks to replace the existing Drugs and Cosmetics Act of 1940. The draft bill which was put on the public domain in July last year seeking feedback from stakeholders contained a provision for taking permission to operate an e-pharmacy.
Load More
